Galaxy Biomedical Investment Co.,Ltd. Posted 14.2 Million Yuan Net Loss in First Quarter of 2022

Galaxy Biomedical Investment Co.,Ltd. (北海银河生物产业投资股份有限公司) (000806.SZ) reported a net loss of 14.2 million yuan in the first quarter of 2022, widening 389.1% year-on-year.

Meanwhile, the company posted 322 million yuan in revenue, up 80.6% year-on-year.

At the end of the reporting period, it had 1.7 billion yuan in total assets and 2.6 billion yuan in total liabilities, with a liability-to-asset ratio of 153.4%.